Davos, 19 January 2023 – Gavi, the Vaccine Alliance announced today the launch of INFUSE 2.0,an innovation scaling hub to accelerate immunisation systems upgrades for the world’s most in-need countries.
INFUSE 2.0 features a collective of commercial and philanthropic investors focused on supporting global health entrepreneurs. The initiative also introduces a first-of-its-kind digital platform to simplify connections between communities, innovators and the private sector to make it easier and faster to share expertise. Impact evaluators will also help start-ups, investors and stakeholders better track and amplify the impact of their innovations on immunisation and global health.
By 2030, INFUSE 2.0 expects to secure at least US$ 500 million in private investment to promote access to new and under-used vaccines and immunisation innovations in the fight against deadly and debilitating infectious diseases.“The pandemic has rolled back years of progress improving vaccine coverage in the world’s most vulnerable countries,” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance. “With millions more children now at risk of deadly, preventable diseases, we need to ensure the most promising, most scalable innovations reach the countries that need them, urgently. INFUSE 2.0 can do just that, bringing together investors looking for impact with entrepreneurs who can deliver it to help protect children across the world.”
The new initiative builds on Innovation for Uptake, Scale and Equity in Immunisation (INFUSE) 1.0, launched in 2016, which has cultivated a community of start-up innovators overcoming vaccine delivery challenges. Initial investments in INFUSE totalled more than US$ 60 million, leading to more than US$ 200 million in follow-on funding for global health innovators.
INFUSE 1.0 also mobilised investments and support from commercial and philanthropic entities including Google.org, Mastercard, NEC, Tencent and the UPS Foundation.
According to the United Nations, the COVID-19 pandemic erased five years of human development progress globally. Impacts to already-fragile government services in vulnerable communities resulted in the largest backslide in childhood vaccinations in three decades.
Today, INFUSE 2.0 launches to address immediate country needs and brace immunisation systems against further shocks, strengthening and scaling services and solutions faster than ever before.
“Beyond the financial support, INFUSE helped us cultivate partnerships with Ministries of Health in Bangladesh and Ghana, as well as technology powerhouses NEC and Arm. Together, we’re boosting use of real-time service delivery data for vaccine verification and ensuring that every vaccine reaches children who need them,” said Toby Norman, Co-founder and CEO, Simprints Technology Ltd.
INFUSE 2.0 debuts with the support of leading corporates:
“We are pleased to announce a new collaboration between Project Last Mile and Gavi INFUSE, made possible by a US$ 1.5 million grant from The Coca-Cola Foundation to Project Last Mile.” said Adrian Ristow, Executive Director of Project Last Mile. “With Project Last Mile already having reached over 40 million lives through more than 40 projects in Africa alongside USAID, the Global Fund, PEPFAR, and the Bill & Melinda Gates Foundation, this is another exciting milestone in PLM’s journey in supporting the scaling of immunisation innovation.”
While the pandemic brings global health to a critical juncture, Gavi’s work stabilising disrupted health and immunisation systems is yielding promising results:
In 2023, strengthening worldwide immunisation systems through digital innovation is a priority among G7 and G20 countries. INFUSE 2.0 offers a means to introduce these innovations at scale.
Within INFUSE’s unique scaling-hub experience, Gavi invites stakeholders to explore critical roles:
Learn more and join the INFUSE community at www.gavi.org/investing-gavi/infuse.